Skip to search formSkip to main contentSkip to account menu

Oncolytic HSV-1 rRp450

Known as: rRp450 
A gene therapy agent containing an attenuated, replication-competent, genetically engineered mutant form of the Herpes simplex virus 1 (HSV-1) strain… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Oncolytic viruses are emerging as a potential new way of treating cancers. They are selectively replication-competent viruses… 
Highly Cited
2008
Highly Cited
2008
Oncolytic herpes simplex virus (oHSV) mutants are under development as anticancer therapeutics. One such vector, rRp450, is ICP6… 
Highly Cited
2002
Highly Cited
2002
Herpes simplex virus 1 (HSV‐1) infection of cancer cells results in viral replication with cell destruction and liberation of… 
2001
2001
rRp450 is an oncolytic herpesvirus that expresses the CYP2B1 cDNA, responsible for bioconverting cyclophosphamide (CPA) into the… 
2001
2001
rRp450 is an oncolytic herpesvirus that expresses the CYP2B1 cDNA, responsible for bioconverting cyclophosphamide (CPA) into the… 
Highly Cited
2000
Highly Cited
2000
Cellular delivery of a replication-conditional herpes simplex virus type 1 (HSV-1) vector provides a means for gene therapy of… 
Highly Cited
2000
Highly Cited
2000
Herpes simplex virus type 1 (HSV-1) replication within tumors can mediate tumor regression (oncolysis). The genetically… 
Highly Cited
1999
Highly Cited
1999
Multimodal therapy is generally more effective than single-agent treatment for cancer. rRp450 is an engineered herpes simplex…